|  |
| --- |
| **Table A3. Multivariate analysis for favorable risk cohort, matched** |
| Variable |  | HR (95% CI) | P-value |
| Treatment | BT | Reference |  |
|  | EBRT alone | 1.142(0.741-1.759) | 0.548 |
|  | RP alone | 0.855(0.559-1.309) | 0.472 |
|  | RP and PLND | 0.793(0.489-1.287) | 0.348 |
| Race | Black | Reference |  |
|  | White | 0.665(0.498-0.887) | 0.006 |
| Facility type | Community Cancer Program | Reference |  |
|  | Comprehensive Community Cancer Program | 1.170(0.704-1.935) | 0.548 |
|  | Academic/Research Program | 0.516(0.302-0.880) | 0.015 |
|  | Integrated Network Cancer Program | 0.650(0.340-1.243) | 0.193 |
| Geography | Northeast | Reference |  |
|  | Middle Atlantic | 1.490(0.518-4.263) | 0.462 |
|  | South Atlantic | 1.450(0.522-4.022) | 0.476 |
|  | East North Central | 1.800(0.634-5.084) | 0.270 |
|  | East South Central | 1.190(0.392-3.608) | 0.760 |
|  | West North Central | 2.040(0.639-6.544) | 0.228 |
|  | West South Central | 1.110(0.344-3.596) | 0.859 |
|  | Mountain | 1.020(0.114-9.240) | 0.983 |
|  | Pacific | 1.130(0.354-3.577) | 0.841 |
| Insurance | No insurance | Reference |  |
|  | Private Insurance | 1.870(0.258-13.581) | 0.535 |
|  | Medicaid | 2.480(0.293-20.996) | 0.405 |
|  | Medicare | 2.410(0.329-17.610) | 0.388 |
|  | Other Government | 2.590(0.266-25.123) | 0.413 |
| Income | $38,000 - $47,999 | Reference |  |
|  | $48,000 - $62,999 | 0.818(0.551-1.216) | 0.320 |
|  | $63,000 + | 0.864(0.573-1.303) | 0.486 |
|  | < $38,000 | 0.956(0.645-1.415) | 0.820 |
| Charleson Deyo comorbidity index | 0 | Reference |  |
|  | 1 | 1.460(1.012-2.114) | 0.043 |
|  | 2+ | 2.680(1.470-4.884) | 0.001 |
| Age |  | 1.060(1.034-1.085) | <0.001 |
| Diagnosis to treatment initiation time | <=90 | Reference |  |
|  | >90 | 1.140(0.829-1.564) | 0.423 |
| Risk cohort | favorable intermediate | Reference |  |
|  | low  | 0.869(0.380-1.985) | 0.738 |
| clinical T stage | T1 | Reference |  |
|  | T2 | 0.948(0.621-1.448) | 0.806 |
| Clinical Gleason score† | 6 | Reference |  |
|  | 7 | 0.905(0.404-2.026) | 0.809 |
| PSA\* | PSA<10 | Reference |  |
|  | PSA10-20 | 1.140(0.597-2.160) | 0.699 |
| *Abbreviations: BT=brachytherapy; EBRT=external beam radiotherapy; RP=Radical Prostatectomy; PLND=Pelvic Lymph Node Dissection; SMD=Standardized mean difference; CI=Confidence Interval; fIR=favorable intermediate risk; LR=low risk* |
| *\* ng/mL* |
| *† combined Gleason score (excluding 4+3, or Gleason pattern 5)*  |